Lexaria Bioscience Corporation (LEXX) News

LEXX, under $2

MORE CASH FOR INFLATED SALARIES AND SHARES TO LINE THEIR POCKETS - F THE INVESTORS -- TOP MGT MAKING $1 MILLION A YEAR PLUS ALL TH E PERKS

https://mailchi.mp/af2a2c58530a/registered-direct-offering-of-common-stock?e=aa4bd7bcad

https://mailchi.mp/168e3489c8b9/recent-glp-1-industry-developments-highlight-the-promise-of-lexaria-biosciences-technology?e=aa4bd7bcad

https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_b00d18d5ada348aba595b6b8022633fb.pdf
Lexaria Bioscience (NASDAQ: LEXX): the new information I have this week is management does not think news on the Material Transfer Agreement (MTA) is late. Chief Executive Officer Rich Christopher said his expectation has been news could be expected in April, May and June period for quite some time. This is excellent news because it means to me that a decision has been made by the unidentified party to the MTA. In the meantime, LEXX announced another direct comparison between their DehydraTECH-lirag lutide with Saxenda® branded liraglutide. A few days earlier, LEXX had announced the start of dosing for this study. This work is being done as part of GLP-1-H25-5 underway in Australia. At the present time, liraglutide is only available injectable form under the brand names Saxenda® and Victoza® both owned by Novo Nordisk. Saxenda® contributed US $1.0 billion in sales and Victoza® added another US $0.8 to Novo Nordisk’s top line. Also, a part of the Australian study added on due to positive results is the study of DehydraTECH-processed Zepbound® with Zepbound® owned by Eli Lilly. Because of projects like this, I continue to believe Lexaria Bioscience (NASDAQ: LEXX) remains a “hot buy” and I would think a little patience is certainly warranted. With a market cap under US $25 million, LEXX seems exceptionally cheap to me given the strong expected news flow and positive momentum in the share price over the past few weeks.

LEXX, under $2

The Next GLP-1 Is A Pill: What to Expect for Weight Loss

Dave Knapp
Mar 7


The world of GLP-1 medications is evolving, and Eli Lilly’s orforglipron is leading the next wave. Unlike Rybelsus, which was the first oral GLP-1 medication but still a peptide, orforglipron is the first non-peptide oral GLP-1 receptor agonist. This key difference means it is more stable in the body, easier to absorb, and potentially offers a new level of convenience for people needing weight loss or blood sugar control.
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_51b6f0993850407ab84754550c5874cb.pdf
"Lexaria Bioscience (NASDAQ: LEXX): as I have been pointing out, LEXX has several significant devel opments on several fronts. The Material Transfer Agreement (MTA) is slightly late but I am not worried yet. I think agreements that require additional scientific work to be done and results to be analysed can be for to six weeks late and we are, say, one third of the way along the timeline. LEXX announced another direct comparison between their DehydraTECH-liraglutide with Saxenda® branded liraglutide. A few days earlier, LEXX had announced the start of dosing for this study. This work is being done as part of GLP-1-H25-5 underway in Australia. At the present time, liraglutide is only available injectable form under the brand names Saxenda® and Victoza® both owned by Novo Nordisk. Saxenda® contributed US $1.0 billion in sales and Victoza® added another US $0.8 to Novo Nordisk’s top line. Also a part of the Australian study added on due to positive results is the study of DehydraTECH-processed Zepbound® with Zepbound® owned by Eli Lilly. Because of projects like this, I continue to believe Lexaria Bioscience (NASDAQ: LEXX) remains a “hot buy” and I would think a little patience With a market cap under US $25 million, LEXX seems exceptionally cheap to me given the strong expected news flow and positive momentum in the share price over the past few weeks. This is a time to “buy-buy,” NOT “bye-bye.”
Ted Ohashi

FYI: Stocktwits has a more active LEXX board than here. See you there.

https://lexariabioscience.com/2025/04/03/lexaria-updates-its-ongoing-human-study-glp-1-h24-4-2/

CBD is such a niche segment though, that isnt going to pump this stock.

Thank you Shawking -- GLTA

Let’s Toke Business Pg. 7
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_8aabd670ed884f8091fdd1669b6ef330.pdf

https://scitechdaily.com/new-cbd-formula-absorbs-six-times-better-and-delivers-faster-relief/?fbclid=IwY2xjawJO1kBleHRuA2FlbQIxMQABHWa4mFNa9sVIejf-tzDvxt2oVSoZ1k1nVWwLUyJTlU270l6Hq-L9orovPw_aem_A3gqDPU0mmDPc91VNsAUVg

SORRY FOR TH E CAPS BUT I NEEED NEW GLASSES. MY GUESS IS THAT A BIG PHARMA ( ASSUMING IT IS A BIG PHARMA) WILL WANT TO DO SOME EVALUATION OF THEIR OWN (ALTHOUGH I HOPE NOT AS IT WILL ADD A GOOD AMOUNT OF TO ANY DEAL BEING MADE). THE HAIL MARY IS A DEAL IN THE WEEKS AHEAD -- IF THEY RUN A TRIAL OR TRIALS OF THEIR OWN THEN I BELIEVE WE ARE NOT TALKING WEEKS BUT MONTHS OR QUARTERS. I HAVE BEEN BUYING SHARES FOR YEARS AND SOME MORE RECENTLY AND HAVE NOT SOLD ANY...MY HOPE/PRAYER/BELIEF IS THAT ONE GOOD DEAL WILL BREAK THE DAM AND OTHERS WILL FOLLOW. I WILL MAKE A NICE PROFIT OR HAVE A BIG WRITE OFF. I DOUBT OUR CEO KNOWS. HOW THINGS ARE GOING TO GO. FWIW - IMHO - GLTU

Shorties getting nervous..lol!

Whats your read on the MTA thats supposedly in the offing with thir DehyraTech?

LEXY has been doing everything well, CBD nicotine etc but only to the extent that no big pharma cares. Too many rat studies are done by many companies with great results that no one will buy into. For years, lexy has been a rudderless ship steered by an overpaid under performing CEO (BUNKA) coupled with Dr John that acts as though Lexy is his personal piggy bank ( while making $300k plus a year). They have never picked an area or two and done something to the point anyone would want to buy in. Salaries for the top three guys today are about a $million a year with results not worth a dime as of today. (PPS $1.38 today with a 30 for 1 reverse split) . I hoped the new CEO would steer the ship but I believe he is a finance guy charting a course to nowhere just like Bunka. I am in too deep to jump ship so I wait for a "Hail Mary " play to get my money back - although with each passing day I see more of my money wasted. Will sit and wait for a miracle at this point - with the latest study. GLTA

Great results. Big pharma is likely impressed although SP manipulators seem to be enjoying themselves today! Be glad to get into some volume from investors that want to hold for more than a quarter at a time!

https://mailchi.mp/5620eaeca9c9/lexarias-dehydratech-tirzepatide-oral-capsules-achieve-comparable-levels-in-bloodstream?e=aa4bd7bcad

500k shares exchanged in the first two minutes of trading?
What's going on?

CB has been and is a self serving leech. - over paid and underperforming for years. Eg. Altria deal wasted tons of resources, time and killed the nicotine division. He should be banned from this company imho

CB was a failed CEO and could not commercialize ViPova tea, Protein bars or any of other CBD Products. The hybertension Phase2/3 is too not started and he jumped on GLP-1 drugs hype, once that is gone, he will jump on something else. IF the technology is that great, why not get license deal like others have got.

LEXX was unsuccessful with CBD because it wasn't clinically tested and approved for a particular medical affliction. The idea with the oral Liraglutide and/ or CBD for Hypertension is the drugs, after testing and approval, would be the only oral drugs of their kinds in the world and could be subscribed by doctors for whatever they are approved to treat. i.e. hypertension, weight loss, T2 diabetes amongst many other afflictions being discovered all the time! IMO It's definitely a good side bet for them.
https://lexariabioscience.com/2025/02/20/lexarias-strategic-business-pursuit-of-dehydratech-liraglutide/

Granted new mgmt...but I feel like you might be right. I would like to see it, but seems like an empty threat simply because they could have already had their own products (NSAIDs, ED drugs) if they really wanted to be a manufacturer/producer. If they were serious, and wanted to make products, they would have jumped at knocking off existing drugs when the FDA approved their tech as not altering the carrier drug. Plus, historically, ViPova tea, TurboCBD, Chrgd...not exactly successful products. Their primary goal is still licensing. Maybe the idea of a competing at a product level speeds up an offer?

The line about developing their own products -- not too sure about that https://lexariabioscience.com/2025/02/27/the-global-revolution-in-healthcare-driven-by-glp-1-drugs-and-the-role-of-lexaria-bioscience/

https://mailchi.mp/99c620a576e3/ethics-board-approval-received-for-dehydratech-tirzepatide-glp-1-study-arm?e=aa4bd7bcad

My guess is more dilution, high R&D expenses by Dr John for rat studies on multiple fronts ( good but big pharma is not. impressed by binders filled with various rat studies) and mgt salaries just for Bunka, Dr John and the new CEO at about a million a year plus perks. A miracle if I get my money back. IMHO GLTA

Can someone explain to me why this is dropping like a rock?

U:LEXX Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world’s first-ever orally-dosed liraglutide

Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.

“Our ability to work with liraglutide, which went off-patent last year, is an opportunity that does not often present itself,” said Rich Christopher, CEO of Lexaria. “Lexaria has already demonstrated that our unique DehydraTECH technology seems to deliver potent oral delivery performance characteristics to liraglutide. This opens the door to the possibility of Lexaria developing and selling the world’s first oral capsule or tablet version of liraglutide.”

As part of that strategic business decision, Lexaria has already filed certain patent applications related to DehydraTECH-enhanced oral liraglutide which, if granted, will further support Lexaria’s ability to commercialize oral DehydraTECH-liraglutide. Presently, there is no oral version of liraglutide available commercially anywhere in the world and Lexaria is hopeful that potential new patent awards in this sector could be of strategic value to the Company.

Lexaria’s patent applications are reinforced by the successful animal study results announced on November 20, 2024 that evidenced superior pharmacodynamic (“PD”) performance. In that study, DehydraTECH-liraglutide outperformed the Rybelsus® control group by week 12 both in terms of blood sugar and body weight control, by 11.53% (p

LEXX under $2

The only way Teddy gets interviews is by writing what the MGT wants...

It is known every time this dick head releases his report, the price goes down by 10-15. Both the Chris have been using him to dilute

Why I think Lexaria Bioscience deserves a market cap many times higher…………………..…………p 7
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_35ed41ca581a44afa5feb3df3fe46379.pdf

https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/

More patents: https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/

https://mailchi.mp/lexariabioscience.com/lexaria-biodistribution-study-for-dehydratech-glp-1-is-underway?e=aa4bd7bcad

https://mailchi.mp/lexariabioscience.com/lexaria-updates-its-ongoing-human-study-glp-1-h24-4?e=aa4bd7bcad

CEO LETER ; THINGS A RE GREAT! https://lexariabioscience.com/2025/01/30/lexaria-releases-annual-letter-from-the-ceo-3/

S-3 Filed with SEC This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a "shelf” registration or continuous offering process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $50,000,000.
FORM S-3
REGISTRATION STATEMENT. https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000146.htm

https://www.theguardian.com/society/2025/jan/20/weight-loss-jabs-linked-to-reduced-risk-of-42-conditions-including-dementia

I wish they would add before/after muscle mass measurements to their Diabetes and Weight Loss testing parameters.

I would also be interested to see if they can somehow get involved in testing their GLP-1 pill to help treat addiction:

https://pennstatehealthnews.org/2024/04/qa-can-weight-loss-drugs-help-in-addiction-treatment/

Lexaria's January Presentation
https://d2ghdaxqb194v2.cloudfront.net/2978/195874.pdf

https://mailchi.mp/lexariabioscience.com/lexarias-human-glp-1-study-5-receives-independent-review-board-approval?e=aa4bd7bcad

Did they diluted this morning? Volume was around 2 million already early morning.

Just the salaries for Bunka, Dr J and Christopher are close to One million/yr plus perks and stock... thus one reason for a another raise...like these three need one.

Dr J has been on a do everything expedition for R & D as though $ is free - of course to him it is. Has filled a lot of binders but that is all.

It would be easy to accept if it is for FDA phase 1b IND studies.

Yeah, that was disappointing. I’m hoping it’s just early traders getting scared, but I don’t know.